A Novel Desensitization Protocol for Infliximab Hypersensitivity in a 13-Year Old Patient with Pustular Psoriasis

Author(s): Sapan Kumar Behera, Sandhiya Selvarajan*, Jerene Mathews, Chandana Shajil, Saibal Das, Malathi Munisamy, Alphienes Stanley Xavier.

Journal Name: Current Drug Safety

Volume 14 , Issue 2 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Drug hypersensitivity reactions to infliximab have been reported in pediatric patients. At times, these patients may need infliximab administration in spite of hypersensitivity. However, only a few reports of desensitization protocols are available in the literature in pediatric patients.

Case Report: We report a case of immediate hypersensitivity reaction to intravenous infliximab in a 13-year-old child suffering from pustular psoriasis who eventually underwent a 14 step desensitization protocol for the administration of infliximab in a pediatric intensive care unit.

Results and Conclusion: Although our desensitization protocol was safe and effective, we recommend the entire desensitization procedure to be performed under the supervision of experienced personnel in a pediatric intensive care unit. Future studies with larger sample size are needed to confirm our findings.

Keywords: Desensitization, infliximab, monoclonal antibody, pediatric, psoriasis, BAT.

[1]
Remicade (Infliximab) prescribing information [cited 2017 Dec 30]. Available from:. https://www.accessdata.fda.gov/-drugsa-tfda_docs/label/2013/103772s5359lbl.pdf
[2]
Napolitano M, Megna M, Balato A, et al. Systemic treatment of pediatric psoriasis: A review. Dermatol Ther 2016; 6(2): 125-42.
[3]
Rott S, Küster RM, Mrowietz U. Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko. Br J Dermatol 2007; 157(1): 191-2.
[4]
Krajcovicova A, Hlavaty T, Zelinkova Z, Letkovsky J, Huorka M. Delayed hypersensitivity reaction after initial dose of infliximab: A case report. Eur J Gastroenterol Hepatol 2014; 26(4): 485-7.
[5]
Ally MR, Betteridge JD, Veerappan GR. Delayed hypersensitivity reaction with infliximab: Unusual to occur after initial dose. Inflamm Bowel Dis 2012; 18(8): E1592-3.
[6]
Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: Systematic review. J Crohn’s Colitis 2015; 9(9): 806-15.
[7]
Puxeddu I, Giori L, Rocchi V, et al. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol 2012; 108(2): 123-4.
[8]
Steenholdt C, Svenson M, Bendtzen K, Thomsen OØ, Brynskov J, Ainsworth MA. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn’s disease. J Crohn’s Colitis 2012; 6(1): 108-11.
[9]
Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol 2003; 98(6): 1315-24.
[10]
Yilmaz DY, Casillas AM, Bahna SL. Successful desensitization to infliximab in 14 subjects. J Allergy Clin Immunol 2009; 123(2): S237.
[11]
Brennan PJ, Rodriguez BT, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124(6): 1259-66.
[12]
Caimmi SME, Caimmi D, Riscassi S, Marseglia GL. A new pediatric protocol for rapid desensitization to monoclonal antibodies. Int Arch Allergy Immunol 2014; 165(3): 214-8.
[13]
Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn’s disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7(1): 34-7.
[14]
Williams SJ, Khokhar A, Gharib A. Successful rapid desensitization to intravenous bevacizumab using a 14-step protocol: Case report. J Allergy Clin Immunol Pract 2017; 5(6): 1746-7.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 2
Year: 2019
Page: [158 - 162]
Pages: 5
DOI: 10.2174/1574886314666190119115632
Price: $58

Article Metrics

PDF: 65
HTML: 2